Incidence and characteristics of thyroid dysfunction following interferon therapy in patients with chronic hepatitis C

Internal Medicine

Volumn 37, Issue 3, 1998, Pages 246-252

  Amenomori, Masahiro ^a   Mori, Toru ^a   Fukuda, Yoshihiro ^a   Sugawa, Hideo ^a   Nishida, Naoshi ^a   Furukawa, Motonobu ^a   Kita, Ryuichi ^a   Sando, Takehiro ^a   Komeda, Toshiki ^a   Nakao, Kazuwa ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Autoimmune thyroid disorder; Cytokine; Destructive thyroiditis; Interferon induced thyroid dysfunction

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; LIOTHYRONINE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; THYROGLOBULIN ANTIBODY; THYROID ANTIBODY; THYROTROPIN; THYROXINE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOIMMUNITY; DRUG INDUCED DISEASE; FEMALE; FREE THYROXINE INDEX; HASHIMOTO DISEASE; HEPATITIS C; HUMAN; IMMUNOPATHOGENESIS; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; SUBCUTANEOUS DRUG ADMINISTRATION; THYROID DISEASE; THYROID FUNCTION TEST; THYROTROPIN BLOOD LEVEL;

EID: 7144260405     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.37.246     Document Type: Article

References (27)

1. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, doubleblind, placebo-controlled trial. N Engl J Med 321: 1506, 1989.
2. Burman P, Tötterman TH, Öberg K, Karlsson FA. Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metab 63: 1086, 1986.
3. Fentiman IS, Balkwill FR, Thomas BS, Russell MJ, Todd I, Bottazzo GF. Anautoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur J Cancer Clin Oncol 24: 1299, 1988.
4. Schultz M, Müller R, von zur Mühlen A, Brabant G. Induction of hyperthyroidism by interferon-α-2b. Lancet i: 1452, 1989.
5. Mayet WJ, Hess G, Gerken G, et al. Treatment of chronic type B hepatitis with recombinant α-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 10: 24, 1989.
6. Berris B, Feinman SV. Thyroid dysfunction and liver injury following alpha-interferon treatment of chronic viral hepatitis. Dig Dis Sci 36: 1657, 1991.
7. Kamikubo K, Takami R, Suwa T, et al. Case report: silent thyroiditis developed during alpha-interferon therapy. Am J Med Sci 306: 174, 1993.
8. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 102: 2155, 1992.
9. Chung YH, Shong YK. Development of thyroid autoimmunity after administration of recombinant human interferon-α 2b for chronic viral hepatitis. Am J Gastroenterol 88: 244, 1993.
10. Nagayama Y, Ohta K, Tsuruta M, et al. Exacerbation of thyroid autoimmunity by interferon α treatment in patients with chronic viral hepatitis: our studies and review of the literature. Endocr J 41: 565, 1994
11. Kosugi S, Mori T, Imura H. Mechanisms by which low salt condition increases sensitivity of thyroid stimulating antibody assay. Endocrinology 125: 410, 1989.
12. Tran A, Quaranta JF, Benzaken S, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 18: 253, 1993.
13. Fonseca V, Thomas M, Dusheiko G. Thyrotropin receptor antibodies following treatment with recombinant α-interferon in patients with hepatitis. Acta Endocrinologica (Copenh) 125: 491, 1991.
14. Reid I, Sharpe I, McDevitt J, et al. Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2α. Br J Cancer 64: 915, 1991
15. Pichert G, Jost LM, Zöbeli L, Odermatt B, Pedio G, Stahel RA. Thyroiditis after treatment with interleukin-2 and interferon α-2a. Br J Cancer 62: 100, 1990.
16. Todd I, Pujol-Borrell R, Hammond LJ, Bottazzo GF, Feldmann M. Interferon-γ induces HLA-DR expression by thyroid epithelium. Clin Exp Immunol 61: 265, 1985.
17. Rhodes J, Jones DH, Bleehen NM. Increased expression of human monocyte HLA-DR antigens and Fcγ receptors in response to human interferon in vivo. Clin Exp Immunol 53: 739, 1983.
18. Bottazo GF, Pujol-Borrell R, Hanafusa T. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet ii: 1115, 1983.
19. Rung AWC, Jones BM, Lai CL. Effects of interferon-γ therapy on thyroid function, T-lymphocyte subpopulations and induction of autoantibodies. J Clin Endocrinol Metab 71: 1230, 1990.
20. Sáez-Royuela F, Porres JC, Moreno A, et al. High doses of recombinant α-interferon or γ-interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology 13: 327, 1991.
21. Ruiz-Moreno M, Rúa MJ, Moraleda G, Guardia L, Moreno A, Carreño V. Treatment with interferon gamma versus interferons alfa and gamma in children with chronic hepatitis B. Pediatrics 90: 254, 1992.
22. Weber P, Wiedmann KH, Klein R, Walter E, Blum HE, Berg PA. Induction of autoimmune phenomena in patients with chronic hepatitis B treated with gamma-interferon. J Hepatol 20: 321, 1994.
23. Daniels HM, Meager A, Eddleston ALW, Alexander GJM, Williams R. Spontaneous production of tumour necrosis factor α and interleukin-1β during interferon-α treatment of chronic HBV infection. Lancet 335: 875, 1990.
24. Gisslinger H, Gilly B, Woloszczuk W, et al. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clin Exp Immunol 90: 363, 1992.
25. Trinchieri G, Santoli D, Koprowski H. Spontaneous cell-mediated cytotoxicity in humans: role of interferon and immunoglobulins. J Immunol 120: 1849, 1978.
26. Volpé R, Amino N. Round table discussion on "Concepts of Hashimoto disease", in: Nagataki S, Mori T, Torizuka K, Eds. 80 years of Hashimoto Disease. Excerpta Medica, Amsterdam, 1993, p. 553.
27. Taniguchi Y, Murakami T, Nakanishi K, et al. Two cases of hypothyroidism associated with alpha-interferon therapy. Intern Med 31: 373, 1992.